SelectScience
Join Free
Accelerating Science
NewsDrug Discovery & Development

Virtual Biopharmaceuticals Summit 2022: Full meeting agenda for November 22

SelectScience

Scientists from AstraZeneca, Bayer, Eli Lilly, Janssen, Roche, and other leading biopharma companies present on the latest topics biotherapeutic research and development

15 Nov 2022
Dora Wells
Clinical Content Editor

Editorial article

Virtual Biopharmaceuticals Summit 2022: Full meeting agenda for November 22

The full exciting schedule has been announced for the SelectScience® Virtual Biopharmaceuticals Summit, taking place on November 22, in partnership with BioPhorum. Featuring presentations from AstraZeneca, Bayer, Eli Lilly, Janssen: Pharmaceutical Companies of Johnson & Johnson, and Roche scientists among others, this free-to-attend online event offers an interactive forum for scientists and manufacturers to connect, showcase the latest research, and share cutting-edge technology solutions for biopharmaceuticals research and development.

You can look forward to topics including:

  • Novel approaches for therapeutic monoclonal antibody discovery
  • Streamlined methods for binding kinetics
  • The latest trends in cell and gene therapy
  • Mass spectrometry techniques for oligonucleotides and larger nucleic acids
  • The latest in adeno-associated viruses (AAVs) critical quality attribute (CQA) analysis
  • Pharmaceutical compliance, and much more

The Summit will host talks by world-leading scientists, live Q&As, video interviews, interactive resource booths, and unique networking opportunities. Attendees will also be able to view academic and industry posters submitted by our global scientific community, leave comments, ask questions, and prompt collaboration through 1-on-1 chat facilities.

Reserve your free place today

Register now to catch the talks that are most relevant to your work, and read on to learn more about:

Keynote speakers

  • Paul Anderson, Director, Biologics Discovery Automation, Eli Lilly
  • Dr. Andrew Mahan, Associate Director, Janssen: Pharmaceutical Companies of Johnson & Johnson

Agenda

Tuesday, November 22

The Summit sessions take place in two concurrent tracks. Track 1 talks cover a range of topics in both Cell Line Development and Gene Therapy, while Track 2 is focused on Bioanalysis techniques. Times in bold are shown as Greenwich Mean Time (GMT).


 11:30
12:30 (CET)
06:30 (EST)
03:30 (PST)

Opening address & Poster session

 12:00
 13:00 (CET) 
07:00 (EST)
04:00 (PST)

Analysis of critical quality attributes of adeno-associated viruses (AAVs)

Dr. Farihah Haque, Product Specialist for GPC/SEC, Tosoh Bioscience

Pharma compliance

David Grant, Global Product Manager, ELGA LabWater
 12:45
 13:45 (CET) 
07:45 (EST)
04:45 (PST)

Applying a matrix approach for potency assay development for in vivo and ex vivo gene therapies

Dominic Hildebrand, Head of Laboratory / QC & Analytical Development, Bayer
Shihua Lin, Pharmaceutical R&D Scientist, AstraZeneca
Sarah Currie, Account Manager, BioPhorum

Biolayer interferometry as an alternative to surface plasmon resonance in a biopharma regulated environment

Dr. Arnaud Delobel, R&D and Innovation Director, Strategy & Innovation, Quality Assistance S.A.
 13:15
 14:15 (CET) 
08:15 (EST)
05:15 (PST)

Semi-targeted spent media LC-MS assay: Assuring product quality during cell line development for biologics

Keynote: Dr. Andrew Mahan, Associate Director, Janssen: Pharmaceutical Companies of Johnson & Johnson
14:00
 15:00 (CET) 
09:00 (EST)
06:00 (PST)

Go beyond titer and select top producers with favorable quality attributes within 5 days of cloning

Dr. Aurora Fabry-Wood, Product Manager, Cell Line Development, Berkeley Lights
15:00
 16:00 (CET) 
10:00 (EST)
07:00 (PST)

Single cell antibody discovery using ‘Islands of automation'

Keynote: Paul Anderson, Director - Biologics Discovery Automation at Eli Lilly

Recent advances in oligo purity and sequence determination by LCMS: Maximizing throughput, confidence, and coverage

Dr. Peter Rye, Application Engineer, Agilent Technologies

 15:45
 16:45 (CET) 
10:45 (EST)
07:45 (PST)

Virtual coffee break - Connect with fellow attendees

16:05
 17:05 (CET) 
11:05 (EST)
08:05 (PST)

User stories for IT to support cell and gene therapies

David Wallace, Facilitator, BioPhorum
Doan Chau, Global Industry Technical Consultant, Rockwell Automation
Sean Buckley, Chief Information Officer, Immunocore
Fred Dardy, IT Portfolio Architect - Architecture & Emerging Technologies Chapter – PTIX, Roche
Christian Hoferer, Team Head MES & Serialization, Roche
Kim Wilson, Life Sciences Business Consultant, Dassault Systèmes

Developing methods for biosimilarty studies of therapeutic monoclonal antibodies

Dr. Kalhari Silva, Head of Scientific Innovation and Research, Custom Biologics
 16:50
 17:50 (CET) 
11:50 (EST)
08:50 (PST)

A mid-down strategy for the mass spectrometric sequencing of progressively larger nucleic acids

Dr. Dan Fabris, Harold S. Schwenk Sr. Distinguished Chair in Chemistry, University of Connecticut
 17:05
 18:05 (CET) 
12:05 (EST)
09:05 (PST)

Release specifications for plasmids and master cell banks used in gene therapy

Dr. Basak Clements, Associate Director, Janssen: Pharmaceutical Companies of Johnson & Johnson
 17:35
 18:35 (CET) 
12:35 (EST)
09:35 (PST)

Ligand binding assay validation requirements and strategies

Mark Dysinger, Associate Director, Alexion Pharmaceuticals
 17:50
 18:50 (CET) 
12:50 (EST)
09:50 (PST)

Cell and gene therapy validation challenges

Dr. Sharif Ahmed, Director, Process Validation - Global MSAT-Biotech, Bayer
 18:35
 19:35 (CET) 
13:35 (EST)
10:35 (PST)

Poster session

Sponsors

Virtual Biopharmaceuticals Summit 2022: Full meeting agenda for November 22

Register for free to reserve a place today — you’ll be able to drop in and out as you wish during the Summit.

Watch this space for further updates and follow our social media channels:

Spread the word using #BiopharmaSummit

Catch up on the latest techniques and technologies and play your part in improving science communication by leaving a lab product review.

Links

SelectScienceCompany website

Tags

Combinatorial ChemistryCombinatorial chemistry, also known as combichem, is a technique used in drug discovery to create libraries of structurally related compounds. A library is generated by synthesis with a chemical reactor system or by computer-based modeling of compound combinations. When undertaking combinatorial chemistry consider reagents, buffers, resins and standards.Genome AnalysisGenomics, the study of genomes, includes functional genomics, evolutionary genomics and comparative genomics. There are many genomic technologies such as DNA sequencing of whole genomes, computational biology and bioinformatics. DNA and nucleic acids must be isolated and concentrated from cells for analysis with kits, automated analyzers and software. Other useful technologies for studying genomics include PCR, microarrays and electrophoresis.OligonucleotidesOligonucleotides are small nucleic acid polymers, usually less than 20 bases in length. Oligonucleotides can be made via enzymatic cleavage or more commonly by chemical synthesis with polymerases. Their use includes FISH, southern blots, microarrays and as primers in PCR. High fidelity synthesis kits and detection systems are available for easy production and detection, respectively.ProteomicsProteomics is the systemic bioinformatics study of proteins and amino acids, including their structure, size, function and identification. Tools used in proteomics include chromatography, blotting and gels, protein arrays, mass spectrometry and ELISA and associated analysis software. Analyzers and proteomic systems should be sensitive, high resolution, fast and may be automated for high-throughput.Data AnalysisData analysis hardware and software is available to make data processing straight-forward yet powerful. Data software can be used for math and stats, technical graphing and image analysis. In addition, software is available for specific data analysis of electrophoresis, densitometry, ELISA and DNA sequencing.Assay AssemblyAssay Assembly is technique used in drug discovery to develop assays to test the cytotoxicity, genotoxicity, or other activities of a compound on a cell. Assay assembly requires chip assembly, a delivery system and a detection and analysis method. Beneficial features of assay kits or automated systems include high-throughput, high speed and sensitivity and low signal to noise ratio.Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Drug DeliveryDrug Delivery refers to dosage form, route of administration, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. Drug delivery is often approached via the biopharmaceutical or small molecule drug's formulation, but it may also involve medical devices or drug-device combination products. Considerations include instrumentation, software and services. Development SoftwareComputational techniques used in both the chemistry and biology aspects of drug development, for data acquisition, data analysis, processing and storage. Software is used for analysis of ADME results, toxicology, clinical trials and regulatory processes. Scale-upScale-Up is generally defined as the process of transferring the results of the discovery phases of the drug discovery process, obtained on a laboratory scale, to the pilot plant and finally to production scale. Scale-Up uses reactors and pump systems as well as reagents, standards and buffers. Often Scale-Up is provided as a service by Contract Manufacturing Organizations (CMOs). BiopharmaceuticalsBiopharmaceuticals are proteins and other compounds (such as nucleic acids) produced by living organisms that have uses as therapeutics or for in vivo diagnostics. The most well known example of a biopharmaceutical product, and the first to be approved for therapeutic use, was recombinant human insulin.Cell TherapyCell therapy involves using living cells to treat diseases, often by replacing damaged cells or stimulating regeneration. Stem cell therapy and CAR-T cell therapy are examples of cutting-edge treatments in regenerative medicine and cancer immunotherapy. Browse our peer-reviewed product directory to find the best cell therapy tools, compare products, check reviews, and get pricing directly from manufacturers.Assay DevelopmentThe process of proving an assay to be sensitive with respect to the target is known as assay development. The assay should be able to characterize novel compounds and measure the potency of these compounds against a validated biological target.

Related articles